Abbott Laboratories (NYSE:ABT) recently posted second quarter results that beat expectations, albeit slightly. Spinning off the company's pharmaceutical arm into AbbVie exposed a bloated, underperforming giant. Fortunately, the company is making strides to boost profitability and increase its presence in quickly growing markets.
The Street likes the results so far. Watch the slideshow to see if Abbott Labs can continue to impress in the quarters to come.
Cory Renauer owns shares of Abbott Laboratories. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Things to Watch When This Top-Performing 3D Printing Company Reports Q4 Earnings
The company behind the "best 3D printing stock" reports fourth-quarter earnings on Thursday, Feb. 8.
Tech Is Walking Away From Wearables
What we did and didn’t see at CES, and what that means for the biggest trends in the tech industry.
Nintendo Switch Is the Fastest-Selling Console in U.S. History
And it could be on pace to become the best-selling console ever. How has Nintendo worked this magic?